Literature DB >> 870192

Effects of estrone, estradiol, and estriol on hormone-responsive human breast cancer in long-term tissue culture.

M Lippman, M E Monaco, G Bolan.   

Abstract

The effects of estrone, estradiol, and estriol on MCF-7 human breast cancer are compared. In this estrogen-responsive cell line, all three estrogens are capable of inducing equivalent stimulation of amino acid and nucleoside incorporation. Estriol is capable of partially overcoming antiestrogen inhibition with Tamoxifen (lCl 46474), even when antiestrogen is present in 1000-fold excess. Antiestrogen effects are completely overcome by 100-fold less estriol. Studies of metabolism of estrogens by MCF-7 cells revealed no conversion of estriol to either estrone or estradiol. All three steroids bind to a high-affinity estrogen receptor found in these cells. The apparent dissociation constant is lower for estradiol than for estrone and estriol, but all three bind to an equal number of sites when saturating concentrations are used. Tritiated estrogens used in binding studies were shown to be radiochemically pure. We conclude that estriol can bind to estrogen receptor and stimulate human breast cancer in tissue culture. Our data do not support an antiestrogenic role for estriol in human breast cancer.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 870192

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Responsiveness to hormone, growth factor and drug treatment of a human breast cancer cell line: comparison between early and late cultures.

Authors:  A de Cupis; P Pirani; L Fazzuoli; R E Favoni
Journal:  In Vitro Cell Dev Biol Anim       Date:  1998 Nov-Dec       Impact factor: 2.416

2.  Genotoxicity of the some selective estrogen receptor modulators: a review.

Authors:  Serkan Yilmaz; Ilknur M Gönenç; Ebru Yilmaz
Journal:  Cytotechnology       Date:  2014-03-05       Impact factor: 2.058

3.  Body size in relation to urinary estrogens and estrogen metabolites (EM) among premenopausal women during the luteal phase.

Authors:  Jing Xie; A Heather Eliassen; Xia Xu; Charles E Matthews; Susan E Hankinson; Regina G Ziegler; Shelley S Tworoger
Journal:  Horm Cancer       Date:  2012-08-04       Impact factor: 3.869

Review 4.  Autocrine and paracrine growth regulation of breast cancer: clinical implications.

Authors:  C K Osborne; C L Arteaga
Journal:  Breast Cancer Res Treat       Date:  1990-01       Impact factor: 4.872

5.  Estrogen mitogenic action. ii. negative regulation of the steroid hormone-responsive growth of cell lines derived from human and rodent target tissue tumors and conceptual implications.

Authors:  D A Sirbasku; J E Moreno-Cuevas
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000 Jul-Aug       Impact factor: 2.416

6.  Influence of ring substituents on the antitumor effect of dichloro(1,2-diphenylethylenediamine)platinum(II) complexes.

Authors:  M Jennerwein; B Wappes; R Gust; H Schönenberger; J Engel; S Seeber; R Osieka
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

7.  Estrone sulfate: a potential source of estradiol in human breast cancer tissues.

Authors:  S J Santner; D Leszczynski; C Wright; A Manni; P D Feil; R J Santen
Journal:  Breast Cancer Res Treat       Date:  1986       Impact factor: 4.872

8.  [DL-1,2-bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer.

Authors:  R Müller; R Gust; G Bernhardt; C Keller; H Schönenberger; S Seeber; R Osieka; A Eastman; M Jennerwein
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

9.  Studies on the mammary tumor-inhibiting effects of diethylstilbestrol and its mono- and diphosphate.

Authors:  M R Schneider; E von Angerer; J Prekajac; W P Brade
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

10.  Dehydroepiandrosterone and estrone 17-ketosteroid reductases in MCF-7 human breast cancer cells.

Authors:  J H MacIndoe; M Hinkhouse; G Woods
Journal:  Breast Cancer Res Treat       Date:  1990-10       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.